Which stock is cheaper: DIVISLAB or SUNPHARMA?

Based on Price to Earnings, DIVISLAB trades at a P/E of 84.2 while SUNPHARMA trades at a P/E of 36.1.

Does DIVISLAB or SUNPHARMA have higher ROCE?

DIVISLAB generates an ROCE of 25.1% compared to SUNPHARMA's ROCE of 22.1%.

DIVI S LABORATORIES LTD (DIVISLAB) has a market cap of ₹2,47,470 Cr compared to SUN PHARMACEUTICAL IND L (SUNPHARMA) with ₹4,41,478 Cr.

DIVISLABHealthcare

Leads (3/5)

₹9,780.00+1.20%

Market Cap: ₹2,47,470 Cr

SUNPHARMAHealthcare

₹1,777.70+0.95%

Market Cap: ₹4,41,478 Cr

Automated quantitative breakdown of fundamental strengths between DIVISLAB and SUNPHARMA.

Attractive ValuationSUNPHARMA (P/E 36.1)Trades at lower Price-to-Earnings

Capital EfficiencyDIVISLAB (ROCE 25.1%)Superior operating return on capital

Balance Sheet SafetyDIVISLABLower debt-to-equity ratio

Shareholder YieldSUNPHARMA (4.84%)Higher annual dividend yield

Green highlight indicates the stronger metric

Financial Metric	DIVISLAB	SUNPHARMA
Valuation Multiples
Market Capitalization	₹2,47,470 Cr	₹4,41,478 Cr
Price to Earnings (P/E)	84.21	36.07
Price to Book (P/B)	14.81	19.73
Profitability & Capital Efficiency
Return on Capital Employed (ROCE)	25.07%	22.11%
Return on Equity (ROE)	13.84%	12.96%
Operating Profit Margin (OPM)	34.38%	27.39%
Net Profit Margin (NPM)	26.17%	12.40%
Balance Sheet & Solvency
Debt to Equity Ratio	0.00	0.61
Dividend Yield	0.33%	4.84%
Historical Growth
3-Year Sales Growth (CAGR)	16.35%	11.41%
Latest Quarter Financial Results
Quarterly Revenue (30 Jun 2026)	₹3,080 Cr	₹15,184 Cr
Quarterly Net Profit	₹902 Cr	₹2,895 Cr